A1
· ·
血栓与止血学 年第 卷第 期
Laboratory of Thrombosis and Hemostasis, Nanchang 330002, China
Abstract
: COVID⁃19 is an infectious disease caused by severe acute respiratory distress syndrome
coronavirus⁃2 ( SARS⁃CoV⁃2) and characterized by prethrombotic state. COVID⁃19 may often lead to acute
respiratory distress syndrome caused by pulmonary microthrombosis and seldomly give rise to systemic multi
organ function damage and even fatal thrombosis. Immunothrombosis is formed by the interaction of activated
neutrophils and monocytes with platelets and coagulation factors, which is considered to be the main
mechanism of COVID⁃19 induced coagulopathy. Inhibition of immunothrombosis may be benefic for the
treatment of severe COVID⁃19. Therefore,this paper intends to introduce the pathophysiology,diagnosis and
treatment of immunothrombosis in COVID⁃19 induced coagulopathy.
Key words
: COVID⁃19; coagulopathy; immunity; thrombus
自 年 月迄今 已在全球导 凝血 和多
2019 12 ,SARS⁃CoV⁃2 (disseminated intravascular coagulation,DIC)
致确诊 的 新 型 冠 状 病 毒 病 患 者 器官功能障碍[3] 一项纳入 项研究入住 的
新型冠状病毒凝血病与免疫血栓 来自淘豆网www.taodocs.com转载请标明出处.